Bioxcel Therapeutics, INC. (BTAI) — 10-Q Filings

10-Q Filings (6)

• BioXcel's Losses Widen Amidst Plummeting IGALMI Sales — Nov 12, 2025 Risk: high
  BioXcel Therapeutics, Inc. (BTAI) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $57.35 million, up from $48
• BioXcel Fuels Operations with $3.1M Equity Raise Amidst Zero Revenue — Aug 12, 2025 Risk: high
  BioXcel Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss
• BioXcel Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business oper
• BioXcel Therapeutics Q3 2024 Update: Cash Position and Offerings — Nov 14, 2024 Risk: medium
  BioXcel Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $42.46 million as of Septe
• BioXcel Therapeutics Files Q2 2024 10-Q — Aug 6, 2024 Risk: medium
  BioXcel Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business opera
• BioXcel Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  BioXcel Therapeutics, Inc. (BTAI) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. BioXcel Therapeutics reported financial results for the quarter e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX